Assessment Status |
Full HTA submission received from Applicant |
HTA ID |
22046 |
Drug |
Nivolumab |
Brand |
Opdivo® |
Indication |
Is indicated for the adjuvant treatment of adults with muscle invasive urothelial carcinoma (MIUC) with tumour cell PD-L1 expression ≥1%, who are at high risk of recurrence after undergoing radical resection of MIUC. |
Rapid review commissioned |
01/07/2022 |
Rapid review completed |
08/08/2022 |
Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of nivolumab for this indication compared with the current standard of care |
Full pharmacoeconomic assessment commissioned by HSE |
31/08/2022 |
Pre-submission consultation with Applicant |
29/11/2022 |
Full submission received from Applicant |
21/02/2023 |